Abstract 5926
Background
Aberrant methylation is pervasive in cancer and a promising source of diagnostic and predictive biomarkers. Bisulfite conversion, the current standard for detecting methylated cytosines, requires higher DNA input requirements due to destruction of DNA, and is problematic for the low cell-free DNA (cfDNA) recovery from plasma. Enzymatic methyl-seq (EM-Seq) uses enzymatic conversion in place of bisulfite. Here, we compare quality metrics and cancer-associated signals of whole-genome sequenced libraries with bisulfite conversion (WGBS) and EM-Seq.
Methods
We collected blood and isolated cfDNA from 7 healthy controls and 15 participants with cancer. Paired libraries from each participant were prepared using WGBS and EM-seq, were sequenced to a median depth of 1.7x, and processed using a custom bioinformatics pipeline.
Results
The quality of data produced by both methods was largely comparable, including highly correlated methylation levels across CpG islands (average Pearson R = 0.97). However, EM-seq performed better on a number of technical metrics including: higher conversion efficiency, increased alignment quality, and coverage. For library pairs where CNAs were detectable (n = 7), the assessed tumor fractions were similar between the two methods, with 6 out of 7 having estimates within 1.15 fold. WGBS libraries showed evidence of DNA damage, including consistently shorter fragments (7.9 ± 2.1 bp shorter mean length in WGBS relative to paired EM-Seq) and the requirement of more amplification cycles (12 vs 8). Like standard whole genome sequencing, control EM-seq libraries had less variability in genome-wide coverage distributions and preserved the canonical cfDNA fragment length distribution.
Conclusions
Our results show that both approaches produce concordant estimates of methylation levels throughout the genome. However, EM-seq demonstrates a number of advantages, including higher performance in key quality metrics. We conclude that EM-Seq is a suitable method for assessing plasma cell-free methylome in a cancer setting and avoiding bisulfite-associated DNA degradation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Lexent Bio Inc.
Funding
Lexent Bio.
Disclosure
N. Lambert: Full/Part-time employment: Lexent Bio Inc. A. Robertson: Full/Part-time employment: Lexent Bio Inc. R. Srivas: Full/Part-time employment: Lexent Bio Inc. N. Peterman: Full/Part-time employment: Lexent Bio Inc. J. Close: Full/Part-time employment: Lexent Bio Inc. T. Wilson: Full/Part-time employment: Lexent Bio Inc. P. George: Full/Part-time employment: Lexent Bio Inc. H. Wood: Full/Part-time employment: Lexent Bio Inc. B. Wong: Full/Part-time employment: Lexent Bio Inc. A. Tezcan: Full/Part-time employment: Lexent Bio Inc. H. Tezcan: Full/Part-time employment: Lexent Bio Inc.
Resources from the same session
2304 - Synthetic peptide of tumor–associated antigen L6 formulated with polymer-based adjuvant enhances anti-tumor effects in mice
Presenter: Shih-jen Liu
Session: Poster Display session 1
Resources:
Abstract
4419 - Improving detection level of somatic mosaicism in neurofibromatosis type 1
Presenter: Kristina Karandasheva
Session: Poster Display session 1
Resources:
Abstract
5283 - Preclinical pharmacokinetic/pharmacodynamic (PK/PD) relationship of ABN401, a highly selective Met inhibitor, in gastric and non-small-cell lung cancer models
Presenter: JooSeok Kim
Session: Poster Display session 1
Resources:
Abstract
5488 - Transcription factors of Snail family in the regulation of resistance of breast cancer cells to hypoxic conditions
Presenter: Alvina Khamidullina
Session: Poster Display session 1
Resources:
Abstract
5417 - Metastasis is impaired by endothelial-specific Dll4 loss-of-function through inhibition of epithelial-to-mesenchymal transition and reduction of cancer stem cells and circulating tumour cells
Presenter: Liliana Mendonça
Session: Poster Display session 1
Resources:
Abstract
5494 - Identification of novel and known FGFR gene fusions in Chinese non-small cell lung cancer
Presenter: Weixin Zhao
Session: Poster Display session 1
Resources:
Abstract
3412 - WNT pathway mutations (APC/CTNNB1) and immune checkpoint inhibitors (ICI) response in metastatic non-small cell lung cancer (NSCLC) patients.
Presenter: Francisco Javier Ros Montana
Session: Poster Display session 1
Resources:
Abstract
1815 - Leukocytosis as a negative prognostic factor in patients with lung cancer: Which subpopulation of leukocytes is responsible?
Presenter: Filip Kohutek
Session: Poster Display session 1
Resources:
Abstract
5022 - Identification of MET gene amplifications using next-generation sequencing in non-small cell lung cancer patients
Presenter: Sergi Clavé
Session: Poster Display session 1
Resources:
Abstract
4925 - Prognostic role of CD73 in metastatic Non Small Cell Lung Cancer according to the presence of driver alterations
Presenter: Giulia Galli
Session: Poster Display session 1
Resources:
Abstract